Affiliated Cancer Hospital of Shantou University Medical College is the lead sponsor of 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 4. The drugs named most often in its trials are Capecitabine, Liposomal Irinotecan and Nalirifox. The most-studied condition is Colorectal Cancer (CRC).
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
|
Phase 1 | Recruiting | 2023-08 | China |
|
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
NCT07104604 · ClinicalTrials.gov ↗ · Rectal Cancer
|
Phase 2 | Recruiting | 2025-10 | China |
|
Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer
NCT07020468 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)
Drug: Nalirifox |
Phase 4 | Active, closed | 2025-05 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Affiliated Cancer Hospital of Shantou University Medical College is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are Capecitabine (1), Liposomal Irinotecan (1), Nalirifox (1) and Tislelizumab (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.